PAT-SM6 in Patients with Recurrent In-Transit Cutaneous Melanoma
- Conditions
- Recurrent in-transit cutaneous melanomaCancer - Malignant melanomaSkin - Other skin conditions
- Registration Number
- ACTRN12610000733077
- Lead Sponsor
- Patrys Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 9
1.The patient has recurrent in-transit cutaneous melanoma based on diagnosis by cytology or histology. The patient may or may not have asymptomatic distant metastatic disease limited to Stage M1a.
2.The patient is willing and able to provide a pre- and post-treatment tumour biopsy.
3.The patient has an Eastern Cooperative Oncology Group (ECOG) performance status Grade of 0, 1 or 2 at study entry.
4.The patient has provided written informed consent.
5.The patient is age 18 years or older.
6.The patient has a life expectancy of > 3 months.
7.The patient has adequate hematologic function, as defined by: - an absolute neutrophil count >= 1500/mm3 - a platelet count >= 100,000/mm3
8. The patient has a haemoglobin level >9 g/dL.
9.The patient has adequate hepatic function, as defined by: - a total bilirubin level <= the upper limit of normal (ULN) unless due to congenital Gilbert’s syndrome - aspartate transaminase (AST) and alanine transaminase (ALT) levels <= 2.5 x the ULN
10.The patient has adequate renal function, with calculated creatinine clearance (using Cockcroft Gault formula) of >50 mL/min and 0 to 1+ proteinuria.
11.The patient uses effective contraception (per the institutional standard), if procreative potential exists.
12.The patient has adequately recovered from any recent therapy, including surgery, chemotherapy, and radiation therapy.
13.The patient is accessible for treatment and follow-up at the participating centre.
1.The patient has metastatic disease at Stage M1b (lung metastases with normal LDH of <=ULN) or M1c (other distant metastases or any distant metastases with elevated LDH of >ULN). 2. The patient has received chemotherapy or therapeutic radiotherapy within 28 days prior to the first dose of study medication or has ongoing side effects >= Common Terminology Criteria for Adverse Events (CTCAE) (Version 4.0) Grade 2 due to agents administered more than 28 days earlier. 3.Immunosuppressive therapy including corticosteroids within four weeks of screening; 4. The patient has uncontrolled intercurrent illness including, but not limited to: - ongoing or active infection requiring parenteral antibiotics, - symptomatic congestive heart failure (class III or IV of the New York Heart Association classification for heart disease), - unstable angina pectoris, angioplasty, stenting, or myocardial infarction six months prior to the first dose of study medication, - uncontrolled hypertension (systolic blood pressure >160 mmHg, diastolic blood pressure >100 mmHg, found on two consecutive measurements separated by a one week period despite adequate medical support), - clinically significant cardiac arrhythmia including but not limited to: multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia that is symptomatic or requires treatment, CTCAE, Version 4.0, Grade 3, or asymptomatic sustained ventricular tachycardia, - uncontrolled diabetes, - psychiatric illness/social situations that would compromise patient safety or limit compliance with study requirements, 5.The patient has known human immunodeficiency virus positivity. 6.The patient has had a major surgical procedure or a significant traumatic injury within 28 days prior to treatment. 7.The patient is currently or has recently used (within 28 days prior to) a thrombolytic agent. 8.The patient is currently using full-dose warfarin (an exception is low-dose warfarin to maintain patency of pre-existing, permanent, indwelling intravenous catheters; for patients receiving warfarin, the international normalised ratio [INR] should be <1.5). A patient requiring heparin is excluded. A patient receiving antiplatelet agents such as non-steroidal anti-inflammatory drugs including aspirin, clopidogrel and dipyramidole is excluded. 9.Known hemorrhagic diathesis or active bleeding disorder. 10.The patient has any condition, which in the Investigator’s opinion, puts the patient at significant risk, could confound study results, or may interfere with the patient’s participation in the study. 11.The patient has received an Investigational Product within 30 days prior to dosing, or five half-lives of the drug whichever is longer. 12.The patient has a QTc interval of greater than 450 ms (males) and 470 ms (females).
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety - Evaluated using the United States (US) National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0, based on recorded adverse events, and by changes from baseline in the patient?s physical examinations, vital signs, performance status and clinical laboratory assessments.[Continuously throughout the study until Exit Visit on Day 36]
- Secondary Outcome Measures
Name Time Method Describe the pharmacokinetics of PAT-SM6[Before the PAT-SM6 infusion, immediately post-infusion, and at 0.25, 0.5, 1, 2, 4, 8, 12, 18 and 24 hours post-infusion. Additional blood will be collected at 48, and 72 hours post-infusion and Day 4 (prior to tumour biopsy), Day 8 and Day 15 Visits from baseline.];Screen for the development of antibodies against PAT-SM6 (immunogenicity).[Day 1, Day 8, Day 15, Day 22, Day 36 from baseline.];Explore the antitumor activity of PAT-SM6 via clinical assessment and clinical photography (where applicable).[Day 4 and throughout the study until Exit Visit on Day 36.];Assess the pharmacodynamic effect(s) of PAT-SM6 in patient tumour samples and to identify potential predictors (biomarkers) of therapeutic efficacy and/or safety.[Day 4 and throughout the study until Exit Visit on Day 36.]